Table 1 Demographics and clinical characteristics in Phase 1 and Phase 2
Phase 1 | ||
Demographicsa | Total (N = 25) | |
Age (years), mean (SD) | 48 (16.5) | |
Female, n (%) | 15 (60.0) | |
Racial backgroundb, n (%) | ||
White | 21 (84.0) | |
Black or African American | 3 (12.0) | |
Asian | 1 (4.0) | |
American Indian or Alaska Native | 2 (8.0) | |
Other | 2 (8.0) | |
Employment statusb, n (%) | ||
Employed full-time | 18 (72.0) | |
Employed part-time | 2 (8.0) | |
Retired | 3 (12.0) | |
Student | 1 (4.0) | |
Other | 2 (8.0) | |
Clinical characteristicsc | ||
Time since diagnosis (years), mean (SD) | 10.8 (11.8) | |
Asthma severity, n (%) | ||
Moderate | 18 (72.0) | |
Severe | 7 (28.0) | |
Asthma control status, n (%) | ||
Controlled (ACQ score < 1.5 at screening) | 16 (64.0) | |
Uncontrolled (ACQ score ≥ 1.5 at screening) | 9 (36.0) | |
FEV1 (L), mean (SD) | 2.2 (0.8) | |
FEV1% predicted, mean (SD) | 62.1 (11.5) | |
FEV1/FVC, mean (SD) | 0.7 (0.1) | |
Number of patients experiencing exacerbations in the past 12 months, n (%) | 12 (48.0) | |
Number of exacerbations in the last 12 months, mean (SD) | 1.1 (1.6) | |
Phase 2 | ||
Characteristics | 205715 (N = 2270)d, e | 205832 (N = 420)e |
Age, years, mean (SD) | 53.3 (13.12) | 48.8 (14.65) |
Females, n (%) | 1403 (61.8) | 297 (70.7) |
Hispanic or Latino ethnicity, n (%) | 235 (10.4) | 9 (2.1) |
Race, n (%) | ||
White | 1888 (83.2) | 386 (91.9) |
Asian | 279 (12.3) | 6 (1.4) |
Black | 84 (3.7) | 26 (6.2) |
Other | 17 (0.7) | 2 (0.5) |
Missing | 2 (0.1) | 0 (0.0) |
FEV1 (L)f, mean (SD) | 2.0 (0.74) | 2.2 (0.67) |
FEV1% predictedf, mean (SD) | 70.7 (14.29) | 70.9 (11.13) |
Exacerbations in last 12 months, mean (SD) | 1.4 (1.29) | 0.3 (0.72) |
Smoking history, n (%) | ||
Never | 1835 (80.8) | 388 (92.4) |
Former | 430 (18.9) | 32 (7.6) |
Missing | 5 (0.2) | 0 (0.0) |
E-RS: COPD Total Score, mean (SD) | 8.3 (6.30) | 7.2 (5.66) |
ACQ-5, mean (SD) | 2.0 (0.77) | 1.8 (0.61) |